Search Result

Results for "

complement activation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Complement System (20) Akt (3) Autophagy (1) Biochemical Assay Reagents (6) Caspase (1) ERK (1) Formyl Peptide Receptor (FPR) (1) Interleukin Related (1) mTOR (2) NF-κB (1) PI3K (1) SARS-CoV (1) Ser/Thr Protease (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (2) Wnt (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (4) Endocrinology (2) Infection (3) Inflammation/Immunology (20) Metabolic Disease (4) Neurological Disease (2)
Oligonucleotides:	Aptamers (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Complement System FAP LAG-3 VISTA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P1036

Compstatin 3 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 3 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation .

HY-P990025

Empasiprubart ARGX-117	Complement System	Inflammation/Immunology
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .

HY-401424

Cremophor EL-36 Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil	Biochemical Assay Reagents	Others
Cremophor EL-36 is a nonionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). The functions of Cremophor EL-36 include: 1) affecting pharmacokinetics by encapsulating drugs in micelles, changing drug distribution and clearance; 2) activating the complement system and inducing allergic reactions; 3) binding to lipoproteins and interfering with lipid metabolism. Cremophor EL-36 increases drug solubility through micellization, while mediating toxicity through complement activation and lipoprotein interactions .

HY-E70389

Human Kallikrein	Ser/Thr Protease	Cardiovascular Disease Inflammation/Immunology
Human Kallikrein is a serine protease that can be found in plasma and tissue. Human Kallikrein has the potential for the research of blood pressure, complement activation, and mediation and maintenance of inflammatory responses .

HY-P3252A

Pegcetacoplan acetate	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .

HY-E70390

C1s Enzyme masp-2, c1 esterase, c1-esterase	Wnt	Cardiovascular Disease Inflammation/Immunology
C1s Enzyme is a subunit of the complement C1 complex, which activates the complement as a serine protease. C1s Enzyme cleaves LRP5 and LRP6, and thus activates the Wnt/β-Catenin signaling pathway. C1s Enzyme promotes the macrophage M2 polarization and inhibits M1 polarization. C1s Enzyme enhances efferocytosis, exhibits anti-inflammatory activity .

HY-160901

CP-289,503	Complement System	Inflammation/Immunology
CP-289,503 is an inhibitor of the complement C5a receptor with an IC50 of 1 μM. C5a acts as an activator of leukocytes and phagocytes during complement system activation. The C5a receptor can bind to C5a, which can stimulate the upregulation of cell surface integrins and degranulation of inflammatory cells, leading to endothelial cell damage. C5a receptor inhibitors can block C5a signaling and inhibit a variety of inflammatory diseases .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .

HY-P3204

POT-4 1 Publications Verification AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-153098

ARC186	Complement System	Cardiovascular Disease Inflammation/Immunology
ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.

HY-153098A

ARC186 sodium	Complement System	Inflammation/Immunology
ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-153403

Activated A Subunit	Biochemical Assay Reagents	Others
Activated A Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153404

Activated C Subunit	Biochemical Assay Reagents	Others
Activated C Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153406

Activated T Subunit	Biochemical Assay Reagents	Others
Activated T Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153405

Activated DPG Subunit	Biochemical Assay Reagents	Others
Activated DPG Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153402

Activated EG3 Tail	Biochemical Assay Reagents	Others
Activated EG3 Tail can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor 1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P1345A

TLQP-21 TFA 1 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-122700

Factor D inhibitor 6	Complement System	Inflammation/Immunology
Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC₅₀ of 30 nM and a K_d of 6 nM. Factor D inhibitor 6 is inactive against factor B, lassical and lectin complement-pathway activation, and a broad assay panel of receptors, ion channels, kinases and proteases .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-W130878

4-Octylphenol	Complement System Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
4-Octylphenol is a hormone disruptor that has gender-specific effects on male reproductive cells, significantly reducing the mitotic index and the number of spermatogonia. 4-Octylphenol can cause inflammatory damage to fish gills by activating the complement system through the C3a/C3aR axis and the C5a/C5aR1 axis, this leads to complement activation and causes immune suppression due to the imbalance between Th1/Th2 cells and regulatory T cells (Treg)/Th17 cells, as well as inflammatory damage via the Toll-like receptor 7 (Toll-like Receptor (TLR))/IκBα/NF-κB pathway .

HY-153785

NH2-C6-ARC186 sodium	Complement System	Inflammation/Immunology
NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH₂-C₆ that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5 .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-N9481

Lipoteichoic acid	Complement System Autophagy mTOR Akt PI3K ERK Interleukin Related	Infection Metabolic Disease Inflammation/Immunology Cancer
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-A0183

Phosphatidylserine Phospholipids, phosphatidylserines; Serine glycerophosphatides	Akt TGF-β Receptor	Inflammation/Immunology
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses .

HY-P10827

PIC1 PA	Complement System	Inflammation/Immunology
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .

HY-D1056B3

Lipopolysaccharides, from Klebsiella pneumoniae LPS, from bacterial (Klebsiella pneumoniae)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .

Cat. No.	Product Name

HY-L036P

Covalent Screening Library Plus	5,738 compounds
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 5,738 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Covalent Screening Library Plus

5,738 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 5,738 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Cat. No.	Product Name	Type

HY-NP004

Cobra Venom Factor CVF	Native Proteins
Cobra venom factor (CVF) is the complement-activating protein from cobra venom. CVF is a three-chain protein that functionally resembles C3b, the activated form of complement component C3. Cobra Venom Factor can be used for the research of the functions of complement in host defense and immune response as well as in the pathogenesis of diseases .

HY-401424

Cremophor EL-36 Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil	Biochemical Assay Reagents
Cremophor EL-36 is a nonionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). The functions of Cremophor EL-36 include: 1) affecting pharmacokinetics by encapsulating drugs in micelles, changing drug distribution and clearance; 2) activating the complement system and inducing allergic reactions; 3) binding to lipoproteins and interfering with lipid metabolism. Cremophor EL-36 increases drug solubility through micellization, while mediating toxicity through complement activation and lipoprotein interactions .

Cremophor EL-36

Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil

Biochemical Assay Reagents

Cremophor EL-36 is a nonionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). The functions of Cremophor EL-36 include: 1) affecting pharmacokinetics by encapsulating drugs in micelles, changing drug distribution and clearance; 2) activating the complement system and inducing allergic reactions; 3) binding to lipoproteins and interfering with lipid metabolism. Cremophor EL-36 increases drug solubility through micellization, while mediating toxicity through complement activation and lipoprotein interactions .

HY-D1056B3

Lipopolysaccharides, from Klebsiella pneumoniae LPS, from bacterial (Klebsiella pneumoniae)	Carbohydrates
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .

Lipopolysaccharides, from Klebsiella pneumoniae

LPS, from bacterial (Klebsiella pneumoniae)

Carbohydrates

Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .

Cat. No.	Product Name	Target	Research Area

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P1036

Compstatin 3 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 3 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .

HY-P3204

POT-4 1 Publications Verification AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-P1345A

TLQP-21 TFA 1 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-P3252A

Pegcetacoplan acetate	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor 1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P10827

PIC1 PA	Complement System	Inflammation/Immunology
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .

Cat. No.	Product Name	Target	Research Area

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation .

HY-P990025

Empasiprubart ARGX-117	Complement System	Inflammation/Immunology
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-P990076

Lorukafusp alfa APN-301; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9481

Lipoteichoic acid	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	Complement System Autophagy mTOR Akt PI3K ERK Interleukin Related
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin .

HY-A0183

Phosphatidylserine Phospholipids, phosphatidylserines; Serine glycerophosphatides	Animals Source classification	Akt TGF-β Receptor
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses .

Cat. No.	Product Name		Classification

HY-153785

NH2-C6-ARC186 sodium		Aptamers
NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH₂-C₆ that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5 .

HY-153098

ARC186		Aptamers
ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

complement activation

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products